A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

Trump’s ‘most favored nation’ policy is back. Here’s why it failed the first time.

The controversial plan aims to lower drug prices and will surely trigger another fight with pharma.

Women’s health faces growing headwinds, despite jump in venture investment

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.

With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?

Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.

FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory

Who’s in, who’s out and which key positions are still left to be filled in an agency upended.

Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy

But the therapies will need to prove their worth in the clinic over the next few years.